AsclepiX Therapeutics partners with Notal Vision on Home OCT remote monitoring in DME and AMD clinical trials
23. Februar 2021 08:00 ET
|
Notal Vision
Manassas, VA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Notal Vision, Inc. announced today that the company will provide AsclepiX Therapeutics with Home OCT monitoring services through its Notal Vision...
Notal Vision Launches First U.S. Home OCT Longitudinal Study with Patient Self-operated Device
12. Januar 2021 08:00 ET
|
Notal Vision
Manassas, VA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Notal Vision, Inc. announced today that the company initiated the first US-based study using its investigational home-based optical coherence...
AI-based OCT analysis of AREDS2 10-Y follow-on study demonstrates superior performance over retina specialists
25. August 2020 08:00 ET
|
Notal Vision
Manassas, VA, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Data analysis from Age-Related Eye Disease Study 2 10-year Follow-On Study (AREDS2-10Y) participants shows that the Notal Optical Coherence Tomography...
ForeseeHome AMD home monitoring real-world data analysis compares favorably to HOME study
28. Juli 2020 08:00 ET
|
Notal Vision
Manassas, VA, July 28, 2020 (GLOBE NEWSWIRE) -- Real-world data on the performance of the ForeseeHome® AMD Monitoring Program, which helps detect the conversion from intermediate dry to wet...
Home OCT longitudinal home-based study with patient self-operated device has begun
17. Juni 2020 07:30 ET
|
Notal Vision
Manassas, VA, June 17, 2020 (GLOBE NEWSWIRE) -- Notal Vision is proud to announce the enrollment of patients in the first longitudinal home-based study with its investigational home optical...
AI-based Notal OCT Analyzer successfully tracks exudative AMD disease activity across longitudinal data sets from home OCT and in-office OCT devices
25. Februar 2020 06:00 ET
|
Notal Vision
Manassas, VA, Feb. 25, 2020 (GLOBE NEWSWIRE) -- The ability of the Notal OCT Analyzer (NOA™) to accurately track exudative age-related macular degeneration (AMD) disease activity across large...
AI-based retinal fluid analytics of serial Notal Vision home OCT images offers insights into retinal disease dynamics
11. Februar 2020 08:00 ET
|
Notal Vision
Manassas, VA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Longitudinal data on retinal imaging of age-related macular degeneration (AMD) patients using the final form factor of Notal Vision’s home OCT...
CPT codes for home OCT established
08. Januar 2020 08:00 ET
|
Notal Vision
Manassas, VA, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Notal Vision, Inc., a privately held ophthalmic diagnostic services company focused on advancing eye care with precision medicine by extending disease...
Notal Vision secures $25 million in recent funding round for ForeseeHome® and pipeline technologies
11. Dezember 2019 08:00 ET
|
Notal Vision
Manassas, VA, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Notal Vision, Inc., a privately held ophthalmic diagnostic services company focused on advancing eye care with precision medicine by extending disease...
Notal Vision Announces Appointment of Dr. Kester Nahen as Chief Executive Officer
23. Oktober 2019 08:00 ET
|
Notal Vision
Tel Aviv, Israel, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Notal Vision, Ltd., a privately held ophthalmic company focused on advancing eye care with precision medicine by extending disease management from...